PMV Pharmaceuticals, Inc. (PMVP)
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
PMV Pharmaceuticals, Inc.
NASDAQ:PMVPHealthcare · Biotechnology
-2.96%$1.31
AH$1.31+0.00%vs close
Mkt Cap$98.92M
Float66.47M
O/S75.51M
Vol
$ Vol
RVOL
Inst Own45.4%
SI3.4%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$77.74M
Total Assets$116.56M
Free Cash Flow-$73.61M
Debt & Equity
Debt 1%
Equity 99%
Total Debt$838K
Total Equity$104.71M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in PMVP's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$116.56M
Liabilities$11.85M
Accounts Receivable$0
Accounts Payable$3.15M
Inventory$0
PP&E (Net)$1.04M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $1.14M | $1.26M | $650K | $1.28M | $318K | $388K | $338K |
| Gross Profit | $0 | -$1.14M | -$1.26M | -$650K | -$1.28M | -$318K | -$388K | -$338K |
| Gross Margin | - | - | - | - | - | - | - | - |
| Research and Development | $69.88M | $57.38M | $54.63M | $51.67M | $36.19M | $23.61M | $20.76M | $13.85M |
| Selling, General, and Administrative | $16.33M | $26.92M | $24.25M | $24.72M | $20.83M | $11.01M | $5.49M | $5.04M |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $16K |
| Total Operating Expenses | $86.21M | $84.3M | $78.88M | $76.39M | $57.01M | $34.62M | $26.25M | $18.89M |
| Operating Income (EBIT) | -$86.21M | -$85.45M | -$80.13M | -$77.04M | -$58.29M | -$34.94M | -$26.64M | -$18.89M |
| Operating Margin | - | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $6.34M | $10.65M | $11.17M | $3.63M | $449K | $651K | $1.3M | $1.34M |
| Other Income (Expense) | $6.29M | $10.64M | $11.17M | $3.71M | $470K | $508K | $1.29M | $1.36M |
| Income Before Tax (EBT) | -$79.91M | -$74.81M | -$68.96M | -$73.33M | -$57.82M | -$34.43M | -$25.34M | -$17.54M |
| Income Tax Expense | -$2.17M | -$16.1M | $2K | -$9K | $23K | $6K | $8K | $3K |
| Net Income | -$77.74M | -$58.71M | -$68.96M | -$73.32M | -$57.85M | -$34.44M | -$25.35M | -$17.54M |
| Net Income Margin | - | - | - | - | - | - | - | - |
| Supplementary Data | ||||||||
| EPS | -1.48 | -1.14 | -1.44 | -1.61 | -1.28 | -2.40 | -0.59 | -5.80 |
| Diluted EPS | -1.48 | -1.14 | -1.44 | -1.61 | -1.28 | -2.40 | -0.59 | -5.80 |
| Weighted Average OS | 52.54M | 51.58M | 48.01M | 45.59M | 45.14M | 44.78M | 43.00M | 3.02M |
| EBITDA | -$79.78M | -$73.67M | -$67.7M | -$73.01M | -$57.52M | -$34.12M | -$24.96M | -$18.55M |
| EBITDA Margin | - | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $37.98M | $40.88M | $37.71M | $108.3M | $172.47M | $361.42M | $73.28M | $30.31M |
| Short-Term Investments | $74.96M | $128.58M | $165.35M | $132.76M | $124.7M | $0 | $28.21M | $31.6M |
| Cash and Short-Term Investments | $112.94M | $169.45M | $203.06M | $241.05M | $297.16M | $361.42M | $101.49M | $61.91M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $2.28M | $6.2M | $4.35M | $5.95M | $822K | $3.34M | $0 | $0 |
| Total Current Assets | $115.23M | $175.66M | $207.41M | $247.01M | $301.29M | $364.76M | $102.09M | $62.24M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $1.04M | $1.55M | $19.05M | $20.49M | $13.15M | $569K | $739K | $1.02M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $13.84M | $25.5M | $2.5M | $16.91M | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $297K | $235K | $190K | $313K | $221K | $201K | $201K | $201K |
| Total Long-Term Assets | $1.33M | $15.63M | $44.74M | $23.3M | $30.28M | $770K | $940K | $1.22M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $116.56M | $191.29M | $252.15M | $270.31M | $331.57M | $365.53M | $103.03M | $63.46M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $3.15M | $6.58M | $3.24M | $3M | $3.19M | $1.61M | $2.84M | $1.04M |
| Short-Term Debt | $0 | $352K | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $4.53M | $5M | $4.5M | $2.9M | $3.8M | $0 | $0 | $0 |
| Total Current Liabilities | $11.41M | $14.37M | $14.03M | $10.83M | $12.22M | $6.41M | $4.52M | $2.33M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $435K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $168.98M | $107.27M |
| Total Long-Term Liabilities | $435K | $838K | $12.43M | $13.45M | $10.79M | $0 | $168.98M | $107.27M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $11.85M | $15.21M | $26.46M | $24.28M | $23.01M | $6.41M | $173.51M | $109.6M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $107.23M |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained Earnings | -$446.45M | -$368.71M | -$310M | -$241.04M | -$167.73M | -$109.88M | -$75.44M | -$50.09M |
| Comprehensive Income & Other | $84K | $139K | $224K | -$445K | -$78K | $0 | -$3K | -$13K |
| Other Stockholders' Equity | $551.17M | $544.79M | $535.69M | $487.07M | $476.29M | $469M | $4.97M | $3.95M |
| Total Equity | $104.71M | $176.08M | $225.69M | $246.03M | $308.56M | $359.12M | -$70.47M | -$46.14M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $116.56M | $191.29M | $252.15M | $270.31M | $331.57M | $365.53M | $103.03M | $63.46M |
| Supplementary Data | ||||||||
| Total Debt | $838K | $1.19M | $13.29M | $13.98M | $11.19M | $0 | $0 | $107.23M |
| Net Debt | -$37.15M | -$39.69M | -$24.42M | -$94.32M | -$161.27M | -$361.42M | -$73.28M | $76.92M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$77.74M | -$58.71M | -$68.96M | -$73.32M | -$57.85M | -$34.44M | -$25.35M | -$17.54M |
| Depreciation & Amortization | $133K | $1.14M | $1.26M | $315K | $307K | $318K | $388K | $338K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $152K | $0 | $319K |
| Stock-Based Compensation | $5.92M | $8.87M | $12.38M | $10.2M | $5.34M | $1.93M | $908K | $1.08M |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$3.42M | $3.34M | $235K | -$389K | $191K | -$1.23M | $1.8M | $267K |
| Other Working Capital | $4.34M | -$4.93M | $5.19M | -$179K | $3.93M | $385K | $122K | $370K |
| Total Working Capital Change | $914K | -$1.59M | $5.43M | -$568K | $4.12M | -$845K | $1.92M | $637K |
| Other Non-Cash Items | -$2.81M | -$997K | -$5.76M | -$385K | $1.5M | $143K | $70K | -$13K |
| Net Cash from Operating | -$73.58M | -$51.28M | -$55.66M | -$63.76M | -$46.57M | -$32.74M | -$22.07M | -$15.18M |
| Investing Activities | ||||||||
| Capital Expenditures | -$29K | -$655K | -$962K | -$7.98M | -$1.35M | -$148K | -$109K | -$452K |
| Acquisitions | $31K | $251K | $0 | $0 | $0 | $148K | $0 | $0 |
| Purchases of Investments | -$88.2M | -$148.29M | -$220.54M | -$229.2M | -$256.85M | -$14.51M | -$43.45M | -$48.68M |
| Sales of Investments | $158.37M | $202.04M | $170.96M | $235.81M | $114.61M | $42.57M | $46.79M | $70.82M |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | -$148K | $0 | $22.14M |
| Net Cash from Investing | $70.17M | $53.35M | -$50.55M | -$1.37M | -$143.58M | $27.91M | $3.23M | $21.69M |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | - | - | - | - |
| Common Stock Issuance | $505K | $313K | $35.12M | $958K | $2.02M | $223.18M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $456K | $0 | $0 | $6K | $100K | $0 |
| Net Cash from Financing | $505K | $313K | $35.58M | $958K | $2.02M | $292.97M | $61.8M | $0 |
| Forex Effect | $7K | -$35K | $34K | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$2.89M | $2.35M | -$70.59M | -$64.17M | -$188.13M | $288.14M | $42.97M | $6.51M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$73.58M | -$51.28M | -$55.66M | -$63.76M | -$46.57M | -$32.74M | -$22.07M | -$15.18M |
| Capital Expenditure | -$29K | -$655K | -$962K | -$7.98M | -$1.35M | -$148K | -$109K | -$452K |
| Free Cash Flow | -$73.61M | -$51.94M | -$56.62M | -$71.74M | -$47.92M | -$32.89M | -$22.17M | -$15.63M |
| Cash at Beginning | $40.88M | $38.53M | $109.12M | $173.29M | $361.42M | $73.28M | $30.31M | $23.79M |
| Cash at End | $37.98M | $40.88M | $38.53M | $109.12M | $173.29M | $361.42M | $73.28M | $30.31M |